Advancements in Desmoid Tumor Treatment Propel Market Growth to $3.84 Billion by 2028

The desmoid tumors market size has grown strongly in recent years. It will grow from $2.76 billion in 2023 to $2.97 billion in 2024 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to advancements in medical imaging, genetic research and understanding, surgical innovations, awareness and education, patient advocacy.

The desmoid tumors market size is expected to see strong growth in the next few years. It will grow to $3.84 billion in 2028 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to targeted therapies, personalized medicine, expanded international collaborations, regulatory approvals for novel therapies, patient-centric approaches. Major trends in the forecast period include advancements in treatment approaches, precision medicine and biomarker discovery, clinical trials and research initiatives, multidisciplinary treatment teams, patient advocacy and support.

Market Overview -
Desmoid tumors refer to rare non-cancerous (benign) tumors that arise from connective tissue cells, usually in the fascia, which is the tissue that surrounds muscles, nerves, and blood vessels. These tumors are locally aggressive, which means they can grow and invade nearby structures but do not spread to distant parts of the body like traditional cancer.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=13228&type=smp

Rising Global Cancer Incidence Fuels Growth In The Desmoid Tumor Market
The rising cases of cancer are expected to propel the growth of the desmoid tumor market going forward. Cancer refers to a collection of disorders that are defined by the body's aberrant cells growing and spreading out of control. These cells can infiltrate nearby tissues and organs and cause harm. The rising cancer cases worldwide have fueled the demand for effective and advanced chemotherapeutic agents, positively influencing the desmoid tumor market. For instance, in January 2023, according to reports published by the American Cancer Society Inc., a US-based voluntary health organization, 1.8 million new cancer cases were diagnosed in the US in 2020, and 606,520 cancer fatalities. By 2021, it was projected that the number of new cancer cases diagnosed would rise to 1.9 million, and the number of cancer deaths would increase to 608,570. Therefore, the rising cases of cancer are driving the growth of the desmoid tumor market.

Competitive Landscape -
Major companies operating in the desmoid tumors market report are Pfizer Inc., F.Hoffmann-La Roche Ltd., Abbvie Inc., Bayer AG, Novartis AG, Abbott Laboratories, Amgen Inc., Stryker Corporation, Genome And Company , Vertex Pharmaceuticals Incorporated, Eisai Limited, Beckman Coulter Inc., Incyte Corporation , Ipsen Biopharmaceuticals Inc., BeiGene Ltd., Janssen Biotech Inc., Ionis Pharmaceuticals Inc., Ayala Pharmaceuticals Inc., Blueprint Medicines Corporation, Xencor Inc., MacroGenics Inc., Debiopharm Group, Clovis Oncology Inc., Juno Therapeutics Inc., SpringWorks Therapeutics Inc., Loxo Oncology Inc., Mirati Therapeutics Inc., Iterion Therapeutics Inc., Recepta Pharmaceuticals Inc., Cellestia Biotech AG

Increasing Focus On Drug Developments To Drive The Revenues
Major companies operating in the desmoid tumors market are developing innovative drugs such as nirogacestat for the treatment of desmoid tumors to meet the needs of their existing consumers better. Nirogacestat is an oral, small-molecule gamma-secretase inhibitor. For instance, in February 2023, SpringWorks Therapeutics Inc., a US-based clinical-stage biopharmaceutical company, announced a U.S. Food and Drug Administration (FDA) acceptance and priority review of their new drug application (NDA) for nirogacestat for the treatment of adults with desmoid tumors. Nirogacestat is thought to work by blocking the production of notch proteins, which can lead to the death of tumor cells. Desmoid tumors produce high levels of notch protein, which is thought to contribute to their growth. Moreover, nirogacestat provides patients with a new treatment option that can potentially improve outcomes.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/desmoid-tumors-global-market-report

Key Segments -
The desmoid tumors market covered in this report is segmented -
1) By Treatment: Surgery, Radiation Therapy, Anti-Inflammatory Medication, Hormone Therapy, Chemotherapy, Novel Molecular-Targeted Therapy, Other Treatments
2) By Diagnosis: Biopsy, Electron Microscopic Examination, Immunohistochemical Analysis, Other Diagnosis
3) By End-User: Hospitals And Clinics, Specialty Centers, Other End-Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.